Stock IdeasStrong Buy StocksStrong Buy Stocks from Top Wall Street AnalystsLatest stocks with a Strong Buy rating from the top performing 25% of analysts tracked by WallStreetZen
Stock IdeasStrong Buy Stocks
| Analyst / Firm | Company | Price | Rating | Price Target | Upside/Downside | Date |
|---|---|---|---|---|---|---|
Rapport Therapeutics IncRAPP | $34.37 | Strong Buy | $56.00 | +62.93% | a day ago | |
Analyst RankingTop 13% #670 out of 5279 analysts Average Return+13.05% Win Rate46%47 out of 103 Risk vs RewardPoor Good Analyst ColorTruist Securities's Danielle Brill assumed coverage on Rapport Therapeutics (NASDAQ: RAPP) with a Strong Buy rating. The analyst also raised their price target by 27.3% from $44 to $56. Assuming coverage on Rapport Therapeutics, Brill backgrounded that RAP-219 is an attractive, differentiated epilepsy asset, with early efficacy data suggestive of best-in-category potential in focal-onset seizures. Upside optionality in bipolar mania is also visible, the analyst said, which is not reflected in its current projections. | ||||||
Tesla IncTSLA | $800.00 | Strong Buy | $850.00 | +6.25% | a day ago | |
Upgrade to Premium to View MoreStrong buys: Upgrade to Premium to view the rest of today's Strong Buy stocks from Wall Street's top analysts Already have access to Premium? Sign In | ||||||
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.